Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses (Q39011242)

8 September 2017

1 reference

title

Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses (English)

1 reference

8 September 2017

0 references

Anita Riecher-Rössler

series ordinal

object named as

Anita Riecher-Rössler

0 references

publication date

11 November 2016

1 reference

8 September 2017

published in

The Lancet Psychiatry

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

63-72

1 reference

Schizophrenia and oestrogens--is there an association?

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogens and gonadal function in schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Sex steroids and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Hyperprolactinaemia in early psychosis-not only due to antipsychotics.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Prolactin levels in drug-naïve patients with schizophrenia and other psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Oestrogen withdrawal associated psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

What do we really know about late-onset schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

[Sex differences in schizophrenic diseases]

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of oestrogen in women

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Oestrogen effects in schizophrenia and their potential therapeutic implications--review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Epidemiology of puerperal psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Further evidence for a specific role of estradiol in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Can estradiol modulate schizophrenic symptomatology?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Neuroactive steroids: focus on human brain

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estradiol and the developing brain

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Disturbed sexual dimorphism of brain activation during mental rotation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Reversal of normal cerebral sexual dimorphism in schizophrenia: evidence and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Neuroprotective actions of selective estrogen receptor modulators.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogens and memory in physiological and neuropathological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Neuroprotection by estradiol.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Is brain estradiol a hormone or a neurotransmitter?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Non-genomic actions of estrogens and their interaction with genomic actions in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Association of estrogen receptor genes and schizophrenia: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogen augmentation in schizophrenia: a quantitative review of current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogen - a potential treatment for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogen in severe mental illness: a potential new treatment approach

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Oestrogen--a new treatment approach for schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogen and memory in women: how can we reconcile the findings?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogen for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Positive treatment effect of estradiol in postpartum psychosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Contribution of sex hormones to gender differences in schizophrenia: A review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Sex hormones in psychotic men.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Global Consensus Statement on menopausal hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Postmenopausal hormone therapy: risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

A comparison of gynecological variables and service use among older women with and without schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Neuroprotective actions of estradiol revisited

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

17α-Estradiol: a candidate neuroserm and non-feminizing estrogen for postmenopausal neuronal complications

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Prolactin secretion patterns: basic mechanisms and clinical implications for reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

The dopamine hypothesis of schizophrenia: version III--the final common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Stress-reactivity in psychosis: evidence for an affective pathway to psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Increased stress-induced dopamine release in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

From stress to psychosis: whom, how, when and why?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

1 reference

7 January 2021

Prolactin and dopamine: what is the connection? A review article

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Sex differences in stress response circuitry activation dependent on female hormonal cycle

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Estradiol levels in psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2930379-0

7 January 2021

10.1016/S2215-0366(16)30379-0

Identifiers

DOI

1 reference

8 September 2017

1 reference